close

Agreements

Date: 2012-11-28

Type of information:

Compound: assays to support the pre-clinical and clinical development of glutaminyl cyclase (QC) inhibitors for the treatment of Alzheimer’s disease

Company: Evotec (Germany) Probiodrug (Germany)

Therapeutic area: Neurodegenerative diseases

Type agreement: collaboration
services

Action mechanism:

Disease: Alzheimer’s disease

Details: Evotec AG has entered into a collaboration with Probiodrug AG, a privately owned biopharmaceutical company focused on the development of innovative drugs for the treatment of major age related diseases. Under the terms of the agreement, Evotec will set up and validate assays to support the pre-clinical and clinical development of glutaminyl cyclase (QC) inhibitors for the treatment of Alzheimer’s disease. Glutaminyl cyclase is a novel proprietary enzyme target discovered and validated by Probiodrug which plays a crucial role in the pathogenesis of Alzheimer’s disease (AD) as well as potentially other diseases. One year ago, the company has announced results of a Phase 1 single (SAD) and multiple ascending dose (MAD) study of its glutaminyl cyclase inhibitor, PQ912, in healthy volunteers. The Phase 1 trial, conducted in Switzerland, demonstrated that PQ912 is safe and well tolerated after oral dosing. Dose-proportional pharmacokinetics and a strong pharmacokinetic and pharmacodynamic relationship based on QC inhibition were observed in plasma and cerebrospinal fluid.

Financial terms:

Latest news:

Is general: Yes